Description
Pertuzumab, trastuzumab, and hyaluronidase-zzxf is approved to be given with docetaxel or other chemotherapy to treat:
Breast cancer that is HER2 positive. It is used:
• As neoadjuvant therapy (to shrink the tumor before surgery) in adults with locally advanced, inflammatory, or early-stage breast cancer. It is given with chemotherapy.
• As adjuvant therapy in adults with early-stage breast cancer who have a high risk that their cancer will recur (come back). It is given with chemotherapy.
• In adults with metastatic breast cancer that has not been treated with anti-HER2 therapy or chemotherapy. It is given with docetaxel.
Pertuzumab, trastuzumab, and hyaluronidase-zzxf is a fixed-dose combination of pertuzumab and trastuzumab that is given as a subcutaneous injection. It can be given in less time than pertuzumab or trastuzumab, which are given as infusions. For more information about pertuzumab and trastuzumab that may apply to pertuzumab, trastuzumab, and hyaluronidase-zzxf, see the Drug Information Summaries for Pertuzumab and Trastuzumab.
Get Access To PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection In India
Brand Name “PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection” or Generic Name (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection” can be imported for personal use under “Named Patient Program” treatment in Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, India. Contact us at support@southdelhipharma.net, southdelhipharma@gmail.com or call/WhatsApp at +91-9891296838 to get access as per norms.